Comparison of changes in respiratory function and exercise oxygen uptake with Losartan versus Enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

被引:40
作者
Guazzi, M
Melzi, G
Agostoni, P
机构
[1] Ist. Cardiol. dell'Univ. degli Studi, Ctro. Stud. per le Ric. C., Milano
关键词
D O I
10.1016/S0002-9149(97)00781-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In congestive heart failure (CHF), some of the effects of angiotensin-converting enzyme (ACE) inhibitors, such as an increase in exercise oxygen uptake (VO2), are mediated through prostaglandins. Angiotensin (AT(1)) receptor blockers apparently do not share potentiation of this biosystem. We tested whether losartan improves exercise VO2 in CHF and if the effect is the same as for enalapril. Sixteen men with CHF and 8 volunteers, ail nonsmokers and not taking ACE, AT(1) receptor, or cyclooxygenase inhibitors, were randomized to receive placebo, enalapril (10 mg 2 times daily), losartan (50 mg/day), each of these 2 drugs plus aspirin (325 mg/day), aspirin, or the same preparations in a reverse order, each for 3 weeks, with a 3-week washout period between treatments. Pulmonary function and VO2 were assessed at the end of each treatment. In CHF, losartan and enalapril caused a similar improvement of VO2 and exercise tolerance, which was absent in controls and was counteracted by aspirin (prostaglandin inhibition) when obtained with enalapril and not with losartan. While on enalapril, we also detected an increase in the diffusing lung capacity for carbon monoxide, which correlated with changes in VO2 and was antagonized by aspirin, suggesting the possibility that a prostaglandin-mediated functional improvement of the alveolar capillary membrane contributes to the rise in VO2. Thus, losartan is as effective as enalapril for exercise VO2 and exercise tolerance, but the mechanism seems to be dissociated from a prostaglandin biosystem activation. Losartan may represent an advancement in CHF because its efficacy on VO2 is similar to that of enalapril, but is not antagonized by aspirin. (C) 1997 by Excerpta Medica, Inc.
引用
收藏
页码:1572 / 1576
页数:5
相关论文
共 27 条
[1]   Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure [J].
Awan, NA ;
Mason, DT .
AMERICAN HEART JOURNAL, 1996, 131 (01) :177-185
[2]  
Blaufarb Ira S., 1996, American Journal of Cardiology, V77, p8C, DOI 10.1016/S0002-9149(96)00183-X
[3]   THE LUNGS IN CHRONIC HEART-FAILURE [J].
CHUA, TP ;
COATS, AJS .
EUROPEAN HEART JOURNAL, 1995, 16 (07) :882-887
[4]  
CLELAND JGF, 1995, BRIT HEART J, V74, P215
[5]   IRON-DEFICIENCY ANEMIA - ITS EFFECT ON TRANSFER FACTOR FOR LUNG (DIFFUSING CAPACITY) AND VENTILATION AND CARDIAC FREQUENCY DURING SUB-MAXIMAL EXERCISE [J].
COTES, JE ;
DABBS, JM ;
SAUNDERS, MJ ;
HALL, AM ;
ELWOOD, PC ;
MCDONALD, A .
CLINICAL SCIENCE, 1972, 42 (03) :325-+
[6]   LOSARTAN IN HEART-FAILURE - HEMODYNAMIC-EFFECTS AND TOLERABILITY [J].
CROZIER, I ;
IKRAM, H ;
AWAN, N ;
CLELAND, J ;
STEPHEN, N ;
DICKSTEIN, K ;
FREY, M ;
YOUNG, J ;
KLINGER, G ;
MAKRIS, L ;
RUCINSKA, E .
CIRCULATION, 1995, 91 (03) :691-697
[7]   ANGIOTENSIN-II RECEPTOR BLOCKADE - AN INNOVATIVE APPROACH TO CARDIOVASCULAR PHARMACOTHERAPY [J].
EBERHARDT, RT ;
KEVAK, RM ;
KANG, PM ;
FRISHMAN, WH .
JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 33 (11) :1023-1038
[8]   EFFECT OF LOW-DOSE ASPIRIN ON CARDIORENAL FUNCTION AND ACUTE HEMODYNAMIC-RESPONSE TO ENALAPRILAT IN A CANINE MODEL OF SEVERE HEART-FAILURE [J].
EVANS, MA ;
BURNETT, JC ;
REDFIELD, MM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 25 (06) :1445-1450
[9]   Drug therapy - Angiotensin receptors and their antagonists [J].
Goodfriend, TL ;
Elliott, ME ;
Catt, KJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (25) :1649-1654
[10]   HEMODYNAMIC AND NEUROHORMONAL EFFECTS OF THE ANGIOTENSIN-II ANTAGONIST LOSARTAN IN PATIENTS WITH CONGESTIVE-HEART-FAILURE [J].
GOTTLIEB, SS ;
DICKSTEIN, K ;
FLECK, E ;
KOSTIS, J ;
LEVINE, TB ;
LEJEMTEL, T ;
DEKOCK, M .
CIRCULATION, 1993, 88 (04) :1602-1609